3 completed, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Simufilam: new trials by email Literature Review of Simufilam trials Research Report on Simufilam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease simufilam - Alzheimer's Disease | Phase 2 | Terminated | Cassava Sciences, Inc. | 90 | 2022-05-12 | 2025-08-15 |
| Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients Simufilam 100 mg oral tablet, Placebo - Alzheimer Disease | Phase 2 | Completed | Cassava Sciences, Inc. | 220 | 2020-03-24 | 2025-04-22 |
| PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet - Alzheimer Disease | Phase 2 | Completed | Cassava Sciences, Inc. | 64 | 2019-09-09 | 2021-09-29 |
| PTI-125 for Mild-to-moderate Alzheimer's Disease Patients PTI-125, 100 mg tablets - Alzheimer Disease | Phase 2 | Completed | Pain Therapeutics | 13 | 2019-03-07 | 2021-07-07 |
Cassava Sciences, Inc. (3) · Pain Therapeutics (1)
United States (4) · Canada (2)
Lindsay Burns, PhD (3) · Chris Cook, JD (1)
PMID 32920628, PMID 33188449, PMID 36934371
R44AG060878 (2), R44AG065152 (1)